Ra Pharmaceuticals (NASDAQ:RARX) Posts Quarterly Earnings Results, Misses Estimates By $0.05 EPS

Ra Pharmaceuticals (NASDAQ:RARX) issued its quarterly earnings results on Thursday. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.05), Fidelity Earnings reports. The firm had revenue of $3.00 million for the quarter.

Shares of NASDAQ RARX traded up $0.05 during trading hours on Friday, hitting $46.82. The company had a trading volume of 413,300 shares, compared to its average volume of 652,991. Ra Pharmaceuticals has a 1-year low of $11.27 and a 1-year high of $47.35. The company has a quick ratio of 15.30, a current ratio of 15.30 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $2.21 billion, a P/E ratio of -22.73 and a beta of 1.55. The firm’s 50 day moving average is $37.65 and its 200-day moving average is $29.69.

In related news, insider Ramin Farzaneh-Far sold 10,595 shares of the firm’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $46.89, for a total value of $496,799.55. Following the transaction, the insider now owns 8,521 shares in the company, valued at $399,549.69. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Simon Read sold 10,000 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $25.41, for a total value of $254,100.00. Following the completion of the transaction, the insider now owns 16,234 shares in the company, valued at approximately $412,505.94. The disclosure for this sale can be found here. Insiders have sold 43,475 shares of company stock valued at $1,402,939 in the last three months. Insiders own 4.30% of the company’s stock.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

RARX has been the subject of several research reports. Leerink Swann cut shares of Ra Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $48.00 price target for the company. in a research note on Friday, October 11th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $48.00 price target on shares of Ra Pharmaceuticals in a research note on Friday, October 11th. Credit Suisse Group cut shares of Ra Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Tuesday, October 15th. Robert W. Baird cut shares of Ra Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $48.00 price target for the company. in a research note on Thursday, October 10th. Finally, Guggenheim cut shares of Ra Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Thursday. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $45.36.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Featured Article: Float

Earnings History for Ra Pharmaceuticals (NASDAQ:RARX)

Leave a Reply

Your email address will not be published. Required fields are marked *

*